Thermosensitive Embolic Agent for Liver Cancer TACE
Part of Cancer, Digestive system clinical trials.
This trial tests a new heat-sensitive embolic agent used during TACE (a procedure that blocks blood flow to tumors and delivers chemotherapy directly to the liver) for primary liver cancer. It aims to see if the agent is safe and effective for patients who need TACE treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with hepatocellular carcinoma (a type of liver cancer) and need TACE treatment.
- Your liver cancer is at a specific stage (IIb or IIIa) or earlier stages (Ia, Ib, IIa) if surgery, transplant, or ablation are not options for you.
- You have at least one untreated liver tumor that is at least 1 cm in size and no larger than 10 cm.
- You agree to take part in the study and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatments for people with large liver tumors. One is a liver artery chemotherapy infusion and the other is a chemo-embolization procedure. The study will see which approach works better.
This trial tests a new embolization treatment (TATE) against standard therapy for people with intermediate-stage liver cancer that hasn't spread. The goal is to see if TATE works better at controlling the tumor.
This trial is for people with advanced liver cancer (HCC) that has spread outside the liver. It tests whether combining a TACE procedure with immunotherapy and anti-angiogenesis drugs can improve outcomes. You must not have had prior systemic therapy and must have received TACE in a specific time window around starting these drugs.
This trial is collecting information on how well a treatment (likely TACE, a procedure to block the tumor's blood supply) works for people with liver cancer that cannot be removed by surgery. It aims to see how safe and effective it is for patients who haven't had treatment before or who have a first recurrence.
This trial tests whether a liver-directed treatment called TACE (transarterial chemoembolization) after surgery can help prevent liver cancer from coming back in people with high-risk features.
This trial tests a combination of treatments for liver cancer that cannot be removed with surgery. It uses a procedure to block the tumor's blood supply plus two drugs that help the immune system fight the cancer. This may help shrink tumors and slow the disease.
Hear when a new Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.